GRIP Molecular develops a graphene-based electronic biosensor that enables rapid, lab-quality diagnostics for multiple diseases from a single sample at the point-of-care. This technology eliminates the need for complex sample preparation, providing actionable medical information within minutes, facilitating timely therapy decisions without requiring a clinic visit.
Funding
$12.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Existing rapid diagnostic tests often lack the sensitivity and accuracy of lab-based methods, leading to potential false negatives and delayed or inappropriate treatment decisions. Traditional lab tests require specialized equipment, trained personnel, and can take significant time to deliver results, hindering timely intervention, especially in point-of-need settings.
Solution
GRIP Molecular is developing a novel diagnostic platform that enhances the accuracy and speed of pathogen detection at the point-of-need. Their technology utilizes a non-thermal nucleic acid amplification (NTA) process to significantly improve the sensitivity of existing lateral flow assays (LFAs), enabling lab-quality results in minutes. This approach overcomes the limitations of current rapid tests by amplifying the signal, making it easier to detect even low concentrations of pathogens. The GRIP platform is designed to be sample-agnostic, compatible with various bodily fluids, and adaptable for detecting a wide range of infectious diseases. By improving the performance of rapid diagnostics, GRIP aims to provide actionable medical information for timely therapy decisions in diverse settings, including homes, clinics, and pharmacies.
Target Audience
The primary target audience includes healthcare providers in clinics and hospitals, as well as individuals seeking at-home diagnostic solutions for rapid and accurate disease detection.
Features
- Non-thermal nucleic acid amplification (NTA) process for enhanced sensitivity
- Compatibility with existing lateral flow assay (LFA) infrastructure
- Sample-agnostic design, supporting urine, nasal secretions, blood, and saliva
- Rapid results in minutes, enabling timely clinical decisions
- Adaptable to detect a wide array of pathogens, including sexually transmitted infections (STIs) and urinary tract infections (UTIs)
- Low-cost manufacturing, leveraging existing production infrastructure
- Easy-to-use format, requiring no changes to existing in-home diagnostic test procedures